Immuron hires Pullan Consulting to shop IMM-529, cites CDI deal comparables

Immuron Limited (ASX: IMC; NASDAQ: IMRN) added new detail to its investor materials in a July 27, 2026 presentation tied to CEO Steven Lydeamore's appearance at the TechKnow Invest Roadshow in Melbourne, building on decks shared earlier in the month.

The company said it has engaged Pullan Consulting to support partnering IMM-529 in July 2026.¹ It also disclosed that in December 2025 it signed a new research agreement funded by a U.S. Department of Defense sub award with the Naval Medical Research Command and Walter Reed Army Institute of Research.¹ Immuron said it received first revenue in May 2026.¹

To frame a potential IMM-529 licensing deal, Immuron cited a table of past Clostridioides difficile-focused transactions. Among them, it described the NTCD-M3 non-toxigenic C. difficile strain program, noting that in 2023 Destiny Pharma licensed the asset to Sebela Pharmaceuticals under terms including a $175 million upfront payment, $125 million on FDA approval, and up to $225 million in sales milestones plus a profit share structure, with the deal at Phase 3 stage.¹ The company said terms from these historical deals show upfront payments ranging from $1 million to $50 million and milestone payments ranging from $25 million to $570 million, with typical royalties in the mid-to-high single digits.¹

Financial figures from prior disclosures were repeated: FY26 Global Sales Revenue of A$7.7 million, up 6% on prior year, with FY26 Australian Sales of A$5.8 million, up 10%.¹ The company reported U.S. sales of A$1.8 million, up 7% (up 13% in USD), and Canada sales of A$0.2 million, down 55%.¹ Immuron listed cash of A$10.0 million as of 31 December 2025.¹